
    
      Thanks to this registry, it will be possible to collect data at diagnosis and during follow
      up, in order to be able to describe the natural history of AL amyloidosis in a real-world
      setting and to define and validate prognostic models, response and relapse criteria
      applicable at any point of the disease.
    
  